文献速递产科母胎医学

产前住院期间药物血栓预防:支持普遍性血栓预防的论证

"Inpatient pharmacological thromboprophylaxis in the antepartum period: an argument for universal thromboprophylaxis".
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-11-26

静脉血栓栓塞症(VTE)约占孕产妇死亡的近15%。长期产前住院(如子痫前期、未足月胎膜早破等高危妊娠)增加VTE风险。作者主张对所有产前住院患者(除活动性阴道出血或 imminent 分娩风险者外)在入院72小时后讨论并推荐普遍性药物血栓预防(普通肝素或低分子肝素)。

要点

  • VTE占孕产妇死亡近15%,妊娠期生理变化及长期住院增加风险。
  • 对于低/中风险患者,门诊不推荐抗凝;但产前住院期间风险增加。
  • 本研究中心常规在入院72小时后讨论并推荐药物VTE预防,除非活动性阴道出血或临近分娩。

核心结论

  • 产前住院期间采用普通肝素或低分子肝素进行普遍性VTE预防最终最有利于患者安全。

研究设计与样本

  • 本文为论述性文章,基于文献与临床实践论证产前住院期间普遍性药物血栓预防的策略。

主要发现

  • VTE约占孕产妇死亡的近15%,妊娠期凝血因子定量变化及增大子宫压迫血管增加VTE风险,包括深静脉血栓、肺栓塞和卒中。
  • 长期产前住院(如因子痫前期、未足月胎膜早破或其他高危妊娠需求)因患者病情及住院状态增加额外VTE风险因素。
  • 对于有VTE病史或高危血栓倾向的患者,抗凝支持几乎普遍;本文聚焦于通常被认为低或中风险的患者。
  • 作为门诊患者,不推荐对低风险人群进行抗凝;但长期住院增加VTE风险因素。

关键数值与推荐

  • 本研究中心的一般做法是:入院72小时后讨论药物VTE预防的风险、获益和替代方案,并推荐对所有患者实施,除非有活动性阴道出血或临近分娩风险。
  • 门诊低/中风险患者不推荐抗凝。
  • 有VTE病史或高危血栓倾向的患者抗凝支持几乎普遍。

临床怎么用

  • 本研究中心的做法是:产前住院72小时后讨论并推荐药物VTE预防(普通肝素或低分子肝素),除非活动性阴道出血或临近分娩风险。
  • 门诊低/中风险患者不推荐抗凝。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE), a largely preventable condition, accounts for almost 15% of maternal mortalities. The physiologic changes of pregnancy, including quantitative changes in coagulation factors and compression of vasculature by the gravid uterus, cause an increase in risk of VTE, including deep vein thromboembolism (DVT), pulmonary embolism, and stroke (CVA). Long term antepartum admission for preeclampsia, preterm prelabor rupture of membranes (PPROM) or other high-risk pregnancy needs present additional risk factors for VTE due to the patient's medical condition and their inpatient status. Given the near-universal support for anticoagulation in patients with a history of venous thromboembolism or high-risk thrombophilia, we will focus this work on patients generally considered low or moderate risk. As outpatients, we do not recommend anticoagulation for this lower risk population. However, with the increase in risk factors for VTE with prolonged admission, it is our general practice to discuss the risks, benefits, and alternatives of chemical VTE prophylaxis 72 hours after admission and recommend administration to all patients unless they have active vaginal bleeding or are at risk for imminent delivery. Here, we will argue why this strategy of universal VTE prophylaxis during antepartum admission with unfractionated heparin (UFH) or low-molecular weight heparin (LMWH) is ultimately in the best interest of patient safety.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Burd J, Zofkie A. "Inpatient pharmacological thromboprophylaxis in the antepartum period: an argument for universal thromboprophylaxis". Am J Obstet Gynecol MFM. 2024. PMID: 39603528. doi:10.1016/j.ajogmf.2024.101566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。